Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan

Myriad Genetics (NASDAQ: MYGN) announced that Japan's Ministry of Health, Labour and Welfare approved the MyChoice Test as a companion diagnostic for Lynparza (olaparib) in prostate cancer on April 14, 2026.

Rhea-AI Summary

Myriad Genetics (NASDAQ: MYGN) announced that Japan's Ministry of Health, Labour and Welfare approved the MyChoice Test as a companion diagnostic for Lynparza (olaparib) in prostate cancer on April 14, 2026. The approval adds tumor-based HRD/BRCA testing access beyond prior breast and ovarian coverage under Japan's NHI.

This expands testing options for patients with metastatic castration-resistant prostate cancer and may increase identification of PARP inhibitor candidates in Japan.

Positive

• Regulatory approval from MHLW for MyChoice in prostate cancer
• Expanded reimbursement scope beyond breast and ovarian under Japan NHI
• Increased testing options for metastatic castration-resistant prostate cancer patients
• Tumor-based HRD/BRCA testing now available in addition to germline testing

Negative

• Unspecified incremental patient volume — approval does not provide concrete testing uptake figures
• No financial guidance included to quantify near-term revenue impact from the approval

Argus Apr 14 session

+6.97% close to close Open Argus

Details

News Market Reaction – MYGN

On Apr 14, the day this news came out, MYGN closed 6.97% above the previous close.

Data tracked by StockTitan Argus for the Apr 14 session.

Market Context

On Apr 14, the day this news came out, the stock closed 7.0% above the previous close. A strong posi...

Analysis

On Apr 14, the day this news came out, the stock closed 7.0% above the previous close. A strong positive reaction aligns with today’s expansion of MyChoice access for prostate cancer patients in Japan and the pre‑existing oncology focus. The move builds on prior CDx approvals and recent MRD launches, while shares still traded below the 200‑day MA at $6.07 with a price of $4.59. Investors also had to weigh an S‑3 shelf for up to $200,000,000 of securities, which may influence how durable any upside proved over time.

Key Figures

Shelf registration size: $200,000,000 Annual prostate cancer cases: more than 100,000 men Q4 2025 revenue: $209.8M +5 more

Shelf registration size

$200,000,000

S-3 shelf prospectus dated February 24, 2026

Annual prostate cancer cases

more than 100,000 men

New diagnoses per year in Japan

Q4 2025 revenue

$209.8M

Myriad Genetics Q4 2025 results

Full-year 2025 revenue

$824.5M

Myriad Genetics FY 2025, down 2% YoY

Q4 2025 test volume

382,000 tests

Q4 2025, up 2% YoY

2026 revenue guidance

$860–$880M

Company guidance reiterated Feb 23, 2026

2026 adjusted EBITDA guidance

$37–$49M

Guidance provided with FY 2025 results

Current share price

$4.59

Price before this Japan MyChoice news

Historical Context

5 past events · Latest: Apr 09

5 events

1. Apr 09

   Conference data presentations

   24h Move

   -6.9%

   Announced four ovarian cancer abstracts and SGO presence highlighting MRD and registry data.

2. Mar 17

   FDA CDx approval

   24h Move

   -2.9%

   Received FDA approval of MyChoice CDx as Zejula companion diagnostic for ovarian cancer.

3. Mar 02

   Product launch

   24h Move

   +5.6%

   Commercially launched Precise MRD ctDNA test with select community oncologists for breast cancer.

4. Feb 24

   Conference abstracts

   24h Move

   +1.1%

   Highlighted six ASCO‑GU abstracts on Precise MRD, Prolaris, and MyRisk performance data.

5. Feb 23

   Earnings and guidance

   24h Move

   +1.1%

   Reported Q4 and 2025 results, reiterated 2026 revenue and margin guidance and growth drivers.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

companion diagnostic, homologous recombination deficiency, BRCA1/2, National Health Insurance (NHI), +2 more

6 terms

companion diagnostic medical

"approved the use of the MyChoice® Test for prostate cancer patients as a companion diagnostic for Lynparza®"

A companion diagnostic is a medical test designed to identify which patients are likely to benefit from a specific drug or medical treatment, much like a key that shows whether a particular lock will open. For investors, these tests matter because they can increase a drug’s chances of approval and market uptake, create a separate revenue stream, and reduce commercial risk by matching treatments to the patients most likely to respond.

homologous recombination deficiency medical

"order the MyChoice Test to determine homologous recombination deficiency (HRD) status for patients"

A condition in which a cell’s ability to fix certain types of DNA damage is impaired, like a zipper that can’t close properly after being pulled apart. Investors care because tumors with this flaw are often more sensitive to specific drugs and diagnostic tests, making related treatments, companion diagnostics, and clinical trial results potentially decisive for a company’s drug value and future revenue.

BRCA1/2 medical

"determine homologous recombination deficiency (HRD) status for patients with ovarian cancer, and BRCA1/2 status for breast and prostate cancers"

BRCA1 and BRCA2 are human genes that act like cellular repair crews, helping fix damaged DNA; certain inherited changes (mutations) in these genes greatly raise the lifetime risk of breast, ovarian and other cancers. Investors care because these mutations drive demand for genetic testing, targeted therapies, preventive care and screening services, and can influence regulatory, reimbursement and litigation risks across diagnostics, drug development and healthcare markets.

National Health Insurance (NHI) regulatory

"MyChoice testing was only reimbursed under Japan’s National Health Insurance (NHI) for breast and ovarian cancer"

A national health insurance (NHI) is a government-run program that pays for medical care for a country’s residents, like a single, nationwide health subscription that pools money to cover doctor visits, hospital stays and medicines. For investors, NHI matters because it shapes how healthcare providers, insurers and drugmakers get paid, affects patient demand and pricing, and can change regulatory and reimbursement risks that influence company revenues and valuations.

metastatic castration-resistant medical

"a portion of those patients will be diagnosed with or later progress to metastatic castration-resistant (mCRP)"

Metastatic castration-resistant describes a form of cancer that has spread from its original site to other parts of the body and no longer responds to treatments that lower or block the hormones which once slowed its growth. For investors, this matters because it defines a patient population with high unmet medical need, often requiring more intensive, expensive therapies and serving as a key focus for clinical trials, regulatory decisions, and potential drug revenue streams.

PARP inhibitors medical

"expected to expand the number of patients who may benefit from treatment with PARP inhibitors"

PARP inhibitors are a class of cancer drugs that block an enzyme cells use to repair damaged DNA, effectively preventing cancer cells from fixing themselves and causing them to die. Investors watch them because their clinical approvals, safety profiles, patent status, and tests that identify which patients will benefit determine market size and revenue potential—much like backing a tool that only works on certain problems but can be very valuable when it does.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SALT LAKE CITY, April 14, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the use of the MyChoice^® Test for prostate cancer patients as a companion diagnostic for Lynparza^® (olaparib). With this approval, clinicians can now order the MyChoice Test to determine homologous recombination deficiency (HRD) status for patients with ovarian cancer, and BRCA1/2 status for breast and prostate cancers.

“Expanding the MyChoice test into prostate cancer marks an important milestone for Myriad Genetics in Japan,” said Brian Donnelly, Chief Commercial Officer, Myriad Genetics. “Previously, MyChoice testing was only reimbursed under Japan’s National Health Insurance (NHI) for breast and ovarian cancer patients, so this new approval broadens access to critical genomic insights that help clinicians make informed treatment decisions for their patients. This also reflects Myriad’s continued focus on adding high value precision medicine tests to its Cancer Care Continuum portfolio.”

According to the World Cancer Research Fund, more than 100,000 men are newly diagnosed with prostate cancer annually in Japan, and a portion of those patients will be diagnosed with or later progress to metastatic castration-resistant (mCRP).

“The reimbursement approval of MyChoice for prostate cancer provides a new testing option for patients with castration-resistant prostate cancer. In addition to the previously available germline BRCA1/2 testing, the inclusion of tumor-based testing is expected to expand the number of patients who may benefit from treatment with PARP inhibitors,” said Dr. Hiroji Uemura, Project Professor, Department of Urological Oncology, Yokohama City University Graduate School of Medicine.

About the MyChoice Test
The MyChoice Test offers comprehensive homologous recombination deficiency (HRD) testing enabling physicians to identify patients with tumors that have lost the ability to repair double-stranded DNA breaks, resulting in increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors. The MyChoice tests comprise tumor sequencing of the BRCA1 and BRCA2 genes and a composite of three proprietary technologies (loss of heterozygosity, telomeric allelic imbalance and large-scale state transitions). The test is offered for breast, ovarian, and prostate cancer indications in Japan. For more information about Myriad Genetics in Japan, visit myriadgenetics.jp.

About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all. Myriad Genetics develops and commercializes molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. For more information, visit myriad.com.

Myriad Genetics Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements that the inclusion of tumor-based testing is expected to expand the number of patients who may benefit from treatment with PARP inhibitors. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 24, 2026, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.

Investor Contact 
Matt Scalo 
(801) 584-3532 
IR@myriad.com 

Media Contact 
Kate Schraml
(224) 875-4493
PR@myriad.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Did Japan's MHLW approve Myriad's MyChoice Test for prostate cancer (MYGN) on April 14, 2026?

Yes — MHLW approved MyChoice as a companion diagnostic for prostate cancer tied to Lynparza on April 14, 2026. According to Myriad, the approval permits clinicians to order tumor-based HRD/BRCA testing for prostate cancer patients in Japan.

What does the MyChoice approval mean for prostate cancer patients in Japan (MYGN)?

It expands access to tumor-based HRD and BRCA testing for prostate cancer patients in Japan. According to Myriad, this adds a testing option that may help identify more patients eligible for PARP inhibitor therapy with Lynparza.

Was MyChoice already reimbursed in Japan for other cancers before the April 14, 2026 approval (MYGN)?

Yes — prior reimbursement under Japan's National Health Insurance covered MyChoice for breast and ovarian cancer patients. According to Myriad, the new approval broadens that coverage to include prostate cancer clinicians ordering the test.

How might the MyChoice approval affect PARP inhibitor use among prostate cancer patients in Japan (MYGN)?

The approval is expected to expand identification of patients who may benefit from PARP inhibitors by enabling tumor-based HRD/BRCA testing. According to Myriad, tumor testing complements existing germline BRCA1/2 testing and may increase treated patients.

Which biomarkers can the MyChoice Test determine for prostate cancer after MHLW approval (MYGN)?

The MyChoice Test can determine homologous recombination deficiency (HRD) status and BRCA1/2 status in relevant cancers. According to Myriad, clinicians can now use the test to assess HRD/BRCA for prostate cancer treatment decisions tied to Lynparza.

Does the April 14, 2026 announcement from Myriad (MYGN) include projected revenue or testing volumes for Japan?

No — the announcement does not provide projected revenue or specific testing volume estimates for Japan. According to Myriad, the release focuses on regulatory and reimbursement expansion rather than financial forecasts or uptake numbers.